The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
How can drug discovery for psychiatric disorders be improved?
Abstract
Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mechanistic heterogeneity that potentially underlies the existing classification scheme might be limiting our ability to clarify etiology and identify novel therapeutics for several psychiatric illnesses (3).”
From Distinct neuropsychological subgroups in typically developing youth inform heterogeneity in children with ADHD (2012) · cites this paper as [3]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Neuronal Oscillations in Cortical Networks
Buzsáki, G., & Draguhn, A. (2004) · Science · doi:10.1126/science.1099745 · Cited by 6,576
Self-citationDeep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Self-citationMayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.675 · Cited by 2,416
Self-citationChanges in grey matter induced by training
Draganski, B., Gaser, C., Busch, V., Schuierer, G., Bogdahn, U., & May, A. (2004) · Nature · doi:10.1038/427311a · Cited by 2,373
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Pezawas, L., Meyer-Lindenberg, A., Drabant, E. M., Verchinski, B. A., Munoz, K. E., Kolachana, B. S., Egan, M. F., Mattay, V. S., Hariri, A. R., & Weinberger, D. R. (2005) · Nature Neuroscience · doi:10.1038/nn1463 · Cited by 1,980
Self-citationLarge-scale recording of neuronal ensembles
Buzsáki, G. (2004) · Nature Neuroscience · doi:10.1038/nn1233 · Cited by 1,875
Self-citation
Research works printed but not linked: 1
- O'Donnell, P. & Grace, A. A. in Review of Psychiatry Vol 18: Schizophrenia in a Molecular Age. Ed. Tamminga, C. A. 109–140 (American Psychiatric Press, Washington DC, 1999).
Cited by
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Self-citationSubcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Self-citationTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Self-citationScaling Brain Size, Keeping Timing: Evolutionary Preservation of Brain Rhythms
Buzsáki, G., Logothetis, N., & Singer, W. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.002 · Cited by 886
Self-citationZebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
Rihel, J., Prober, D. A., Arvanites, A., Lam, K., Zimmerman, S., Jang, S., Haggarty, S. J., Kokel, D., Rubin, L. L., Peterson, R. T., et al. (2010) · Science · doi:10.1126/science.1183090 · Cited by 778
Metadata
- Authors
- Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., Popoli, M., Prochiantz, A., Richter-Levin, G., Somogyi, P., Spedding, M., Svenningsson, P., & Weinberger, D.
- Affiliations
- Inserm (FR)
- Rutgers, The State University of New Jersey (US)
- University of South Florida (US)
- National Hospital for Neurology and Neurosurgery (GB)
- National Institutes of Health (US)
- University of Pittsburgh (US)
- University of Dundee (GB)
- Emory University (US)
- University of Milan (IT)
- Centre National de la Recherche Scientifique (FR)
- Karolinska Institutet (SE)
- Corresponding author
- Spedding, Michael
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 189-201
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2039643193
- Semantic Scholar
- 6b055b58cc82aab9331b179042a3985bb06b3e33
- Cited by
- 240
- References
- 81
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 12 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 3 · 2015: 8 · 2014: 10 · 2013: 17 · 2012: 30
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychiatric drug discovery, depression, schizophrenia, anxiety, neuropsychiatric disorders, neuroplasticity, translational neuroscience, multidisciplinary approach
- MeSH terms
- Mental Disorders, Consensus Statements as Topic, Humans, Models, Biological, Surveys and Questionnaires, Tranquilizing Agents, Drug Design, Signal Transduction, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How can drug discovery for psychiatric disorders be improved? https://app.cochat.ai/papers/10.1038/nrd2217
- The paper
- Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., Popoli, M., Prochiantz, A., Richter-Levin, G., Somogyi, P., Spedding, M., Svenningsson, P., & Weinberger, D. (2007). How can drug discovery for psychiatric disorders be improved? Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd2217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.